Indirect Comparison of Tobramycin Solution for Inhalation Versus Aztreonam Lysine for Inhalation in the Treatment of Cystic Fibrosis

A Study Comparing the Efficacy and Tolerability of Tobrineb®/Actitob®/Bramitob® Versus TOBI®

NCT00885365 ·Status: COMPLETED ·Phase: PHASE3

Safety of Tobramycin Inhalation Powder (TIP) vs Tobramycin Solution for Inhalation in Patients With Cystic Fibrosis

NCT00388505 ·Status: COMPLETED ·Phase: PHASE3

Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis Subjects

NCT00125346 ·Status: TERMINATED ·Phase: PHASE3

Tobramycin 300 mg Once-a-day (o.d.) Aerosol in Adults With Cystic Fibrosis

NCT01608555 ·Status: COMPLETED ·Phase: PHASE4

Tobramycin Inhalation Solution Administered by eFlow Rapid Nebulizer: Scintigraphy Study

NCT00399945 ·Status: COMPLETED ·Phase: PHASE1

Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years

NCT01082367 ·Status: COMPLETED ·Phase: PHASE3

Evaluation of Short Antibiotic Combination Courses Followed by Aerosols in Cystic Fibrosis

NCT03066453 ·Status: TERMINATED ·Phase: PHASE3

Efficacy of TOBI Podhaler vs. Tobramycin Inhalation Solution

NCT02038803 ·Status: TERMINATED

Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis

NCT01519661 ·Status: COMPLETED ·Phase: PHASE4

Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles

NCT02015663 ·Status: TERMINATED ·Phase: PHASE4

A Single Arm 48-Week Follow-on Safety Study to a Core Study Comparing the Efficacy and Tolerability of Tobrineb®/Actitob®/Bramitob® Versus TOBI®

NCT01111383 ·Status: COMPLETED ·Phase: PHASE3

A Study of the Safety and Efficacy of Tobramycin for Inhalation in Young Children With Cystic Fibrosis

NCT00006280 ·Status: COMPLETED ·Phase: PHASE2

Pharmacokinetic Evaluation of an 8 -Week Treatment With Inhaled Tobramycin

NCT00634192 ·Status: COMPLETED ·Phase: PHASE3

Inhaled Nebulized Tobramycin in Non-cystic Fibrosis Bronchiectasis

NCT02657473 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Study Evaluating Fosfomycin/Tobramycin for Inhalation in Cystic Fibrosis Patients With Pseudomonas Aeruginosa Lung Infection

NCT00794586 ·Status: COMPLETED ·Phase: PHASE2

Pharmacokinetic Evaluation and Tolerability of Dry Powder Tobramycin by a Novel Device in Patients With Non Cystic Fibrosis Bronchiectasis

NCT02035488 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Dose-finding Study to Assess the Efficacy, Safety and Tolerability of Tobramycin Inhalation Powder in Patients With Non-Cystic Fibrosis Bronchiectasis and Pulmonary P. Aeruginosa Infection

NCT02712983 ·Status: COMPLETED ·Phase: PHASE2

Second Open Label Extension to Bridging Study CTBM100C2303

NCT01069705 ·Status: COMPLETED ·Phase: PHASE3

OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis

NCT02054156 ·Status: COMPLETED ·Phase: PHASE3

A Study of the Clinical Benefit of Tobramycin Inhalation Solution

NCT06106789 ·Status: ACTIVE_NOT_RECRUITING

Evaluation of Inhaled Antibiotics on Bacterial Diversity and Richness in the Cystic Fibrosis Lung

NCT02113397 ·Status: TERMINATED

Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF

NCT01641822 ·Status: COMPLETED ·Phase: PHASE3

A Study of Tobramycin Inhalation Powder From a Modified Manufacturing Process Versus Placebo

NCT00918957 ·Status: COMPLETED ·Phase: PHASE3

Nasal Inhalation of Tobramycin in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Colonization

NCT00774072 ·Status: COMPLETED ·Phase: PHASE2

Combined Dry Powder Tobramycin and Nebulized Colistin Inhalation in CF Patients

NCT03341741 ·Status: COMPLETED ·Phase: PHASE3